In a randomized Phase 3 study of 404 patients with discogenic chronic low back pain, including 168 on opioids at baseline, a single intradiscal injection of rexlemestrocel-L with hyaluronic acid produced more than a threefold increase in complete opioid cessation at 36 months versus saline control (p=0.008). The trial had previously met its 12-month primary endpoint of pain reduction, the basis on which the sponsor is seeking approval.
The immediate development is procedural but meaningful: FDA has set an early December meeting to review the opioid reduction and cessation analyses from the first Phase 3 study (MSB-DR003). In parallel, a 300-patient, placebo-controlled confirmatory Phase 3 is enrolling at roughly 40 U.S. sites, with enrollment completion targeted for the coming quarter. The agency has previously agreed that 12-month pain reduction is an approvable indication for this program, and the product holds RMAT designation, positioning it for closer regulatory interaction and the mechanics of rolling review.
Strategically, the company is widening the frame from analgesia to opioid stewardship, aligning with the FDA’s new guidance encouraging the development of non-opioid treatments for chronic pain. Elevating a 36-month opioid cessation signal invites a dialogue about whether opioid-use outcomes can be reflected in labeling or otherwise recognized as clinically meaningful benefits beyond pain scores and function. The tension is obvious: opioid use is influenced by tapering practices, prescriber behavior, and access to alternatives, making causality harder to ascribe than for pain endpoints. The sponsor’s path still runs through replicating the pain effect on the agreed timeframe while building a credible, prospectively captured narrative on opioid sparing that can withstand questions about confounding and durability.
For sites and CROs, the operational footprint is interventional. Standardized intradiscal injection technique, imaging-based eligibility, and consistent adjudication of pain and function are table stakes; adding rigorous, auditable assessment of opioid exposure raises the bar. Expect protocols to lean on ePRO for pain, centralized training for injection procedures, and tighter integration with pharmacy records and state PDMP data to validate cessation claims. The focus on patients with degenerative disc disease of less than five years’ duration narrows screening funnels. It may favor high-volume spine centers and ASCs with established cryostorage and chain-of-custody workflows for cell therapy. For sponsors, the single-administration profile is operationally attractive, but procedural variability across 40 sites is a known source of signal noise in back pain trials. Payers will look for durability, re-intervention rates, and functional gains commensurate with a procedure-based cost structure; any opioid-related claim would be scrutinized for real-world translatability.
The December FDA discussion will be a read-through on how the agency wants opioid-use endpoints handled in chronic pain programs: hierarchy in the statistical plan, definitions of cessation, and acceptable data sources. Watch for protocol amendments in the confirmatory trial that hardwire opioid metrics and for clarity on whether the FDA will consider opioid reduction as supportive evidence or as a distinct clinical benefit. Key risks include placebo responsiveness in CLBP, heterogeneity in standard-of-care opioid management across sites, and the need to reproduce the pain signal in a contemporary cohort while maintaining product supply and temperature control logistics. If the confirmatory study delivers on pain and presents clean, prospectively captured opioid-use data, the program could test whether procedure-based, non-opioid interventions can secure both regulatory traction and payer acceptance in a market under pressure to de-escalate opioid reliance.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
